Verdinexor

Product Description

Verdinexor is a selective exportin-1 (XPO1/CRM1) inhibitor. It potently inhibits influenza virus ribonucleoprotein (vRNP) export by disrupting XPO1-NEP binding and the replication of influenza virus A and B strains in vitro, including H1N1, H5N1 and H7N9 (IC₅₀ values in the range 40 - 420 nM range). Verdinexor limits influenza A virus spread in mouse lung in vivo. In neuroblastoma, verdinexor suppresses cell proliferation and induces cell apoptosis. It also induces P53 nuclear accumulation and induces G₀/G₁ phase cell cycle arrest by activating P53 function. Verdinexor inhibits tumor growth in in vivo mouse models. Orally bioavailable.

Solubility

Preparing Stock Solutions for Verdinexor

The following data is based on the product molecular weight 442.32

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.26 mL	11.30 mL	22.61 mL
5 mM	0.45 mL	2.26 mL	4.52 mL
10 mM	0.23 mL	1.13 mL	2.26 mL
50 mM	0.05 mL	0.23 mL	0.45 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Perwitasari Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo J.Virol. 2014 PMID: 24965445
• Pan XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor. J.Exp.Clin.Cancer Res. 2021 PMID: 34384466